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Abstract
Objective—Conflicting results have been reported for adeno- and adenosquamous carcinomas of 
the cervix with respect to their response to therapy and prognosis. The current study sought to 
evaluate impact of adeno- and adenosquamous histology in the randomized trials of primary 
cisplatin-based chemoradiation for locally advanced cervical cancer.
Methods—Patients with adeno- and adenosquamous cervical carcinomas were retrospectively 
studied and compared to squamous cell carcinomas in GOG trials of chemoradiation.
Results—Among 1671 enrolled in clinical trials of chemoradiation, 182 adeno- and 
adenosquamous carcinomas were identified (10.9%). A higher percentage of adeno- and 
adenosquamous carcinomas were stage IB2 (27.5% versus 20.0%) and fewer had stage IIIB 
(21.4% versus 28.6%). The mean tumor size was larger for squamous than adeno- and 
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adenosquamous. Adeno- and adenosquamous carcinomas were more often poorly differentiated 
(46.2% versus 26.8%). When treated with radiation therapy alone, the 70 patients with adeno- and 
adenosquamous carcinoma of the cervix showed a statistically poorer overall survival (p=0.0499) 
compared to the 647 patients with squamous cell carcinoma of the cervix. However, when treated 
with radiation therapy with concurrent cisplatin-based chemotherapy, the 112 patients with adeno- 
and adenosquamous carcinomas had a similar overall survival (p=0.459) compared the 842 
patients with squamous cell carcinoma. Adverse effects to treatment were similar across 
histologies.
Conclusion—Adeno- and adenosquamous carcinomas of the cervix are associated with worse 
overall survival when treated with radiation alone but with similar progression-free and overall 
survival compared to squamous cell carcinomas of the cervix when treated with cisplatin based 
chemoradiation.
INTRODUCTION
Although adeno- and adenosquamous cancers of the cervix comprise a minority of cervical 
cancers, their relative and absolute frequency has increased over the last 4 decades despite 
the wider application of cervical cancer screening [1,2]. A recent large SEER (Surveillance, 
Epidemiology, and End Results) database study from 1988–2005 found a 1–2 % increase in 
the incidence of adenocarcinoma and adenosquamous carcinomas with each 6 year 
increment. Collectively, adenocarcinoma and adenosquamous cancers totaled 21.3%, 22.9% 
and 24.1%, for the years 1988–1993, 1994–1999 and 2000–2005, respectively [2]. This 
study also reported that patients with adenocarcinoma have a poorer overall survival than 
similarly staged squamous cell cancer patients [2]. Patients with advanced stage 
adenocarcinoma or adenosquamous carcinoma were 21% more likely to die from their 
disease than advanced stage squamous cell cancer patients. In contrast to the SEER data, a 
recent large single institution study (N=423) by Katanyoo et al suggests that, when treated 
according to a standard treatment protocol, adenocarcinoma and adenosquamous carcinomas 
have a similar outcome to squamous cell carcinoma [3].
In 1999, the NCI released a clinical announcement in strongly urging the use of cisplatin-
based chemoradiation for cervical cancer patients requiring radiation for their treatment [4]. 
However, the role of primary chemoradiation for locally advanced adenocarcinoma and 
adenosquamous cancers of the cervix has not been established by level 1evidence. Although 
adeno- and adenosquamous carcinomas were included in randomized trials of cisplatin-
based chemoradiation, there were too few patients with adenocarcinoma and 
adenosquamous histology to allow a subset analysis. Only Peters et al evaluated the role of 
tumor histology in their randomized trial of post-radical hysterectomy adjuvant 
chemoradiation for women with positive nodes, parametria or margins [5]. This 
demonstrated that patients with adenocarcinoma had an apparent poorer 5 year progression-
free survival (40% vs 65%) when treated with radiation alone but similar outcome with 
chemoradiation (80% vs 77%). However, this did not reach statistical significance due to the 
small number of patients with adenocarcinoma.
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Based on their relatively small size, prior retrospective studies of adenocarcinoma and 
adenosquamous cervical cancers have not established a clear role for cisplatin-based 
chemoradiation. In the Katanyoo et al study, concurrent platinum-based chemotherapy did 
not significantly improve overall survival, although only 37.6% of patients received 
chemoradiation [3]. The impact of concurrent chemotherapy during radiation has been 
addressed in other retrospective studies with no apparent improvement although the authors 
have included disclaimers about the regimens employed [6].
Therefore, the current GOG ancillary data study was undertaken to evaluate impact of 
histology in the prospective randomized trials of primary cisplatin-based chemoradiation for 
locally advanced cervical cancer.
METHODS
We retrospectively analyzed GOG trials numbered 85, 120, 123, 165 and 191 [7–11]. 
Patients provided written informed consent consistent with federal, state and local 
institutional requirements. These trials have been reported previously and included patients 
with stage IB2: GOG Trials 123, 191 and stages IIA: GOG Trial 191 and stage IIB-IVA: 
GOG Trials 85,120, 165, and 191. In GOG trials 85 and 120 patients underwent surgical 
staging to exclude para-aortic nodal metastasis and pelvic nodal dissection was optional. 
While in GOG trials 123, 165 and 191 surgical staging was optional and performed on 7.5%, 
18% and 23.7% respectively. Tumor size measured clinically within 0.5 cm was obtained 
before treatment. All patients were treated with a combination of external radiation and 
brachytherapy per protocol guidelines. The duration of external radiation for GOG trials 85, 
120 and 123 required external radiation treatment to be given over 10 weeks, while GOG 
trials 165 and 191 required external radiation treatment to be given over 8 weeks. All 
patients’ tumors underwent central pathologic review for confirmation of histology and 
tumor grade. Due to the small sample size, we wanted to combine patients with 
adenocarcinoma and adenosquamous carcinoma based on the fact that in previous studies 
these two entities had similar patterns of failure, progression-free and overall survival [12]. 
To justify this combination we performed an analysis comparing adenosquamous carcinoma 
with adenocarcinoma. With adenosquamous as the referent, adenocarcinoma patients in the 
PFS model had a HR of 0.93 (95% CI, 0.59–1.48, P=0.769). In the OS model, 
adenocarcinoma patients had a HR of 0.84 (95% CI, 0.52–1.36, P=0.484). In both models 
the histology variables were not significant. Therefore, patients with subgroups of 
adenocarcinoma and adenosquamous carcinoma were combined and compared to patients 
with squamous cell carcinoma.
Categorical variables were compared between the histology groups by the Pearson chisquare 
test [13], and continuous variables by the Wilcoxon–Mann–Whitney test [14]. Overall 
survival was estimated using the Kaplan–Meier method [15]. The Cox proportional hazards 
model was used to evaluate independent prognostic factors and to estimate their 
covariateadjusted effects on progression-free and overall survival [16]. Continuous variables 
exhibiting skewed distribution (i.e. tumor size) were included in the survival model after log 
transformation, and the nonlinearity of the effect of continuous variables was assessed using 
restricted cubic splines. All statistical tests were two-tailed with the significance level set at 
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α=0.0499. Statistical analyses were performed using the R programming language and 
environment [17].
RESULTS
One thousand six hundred and seventy-one patients treated on the GOG studies were 
analyzed of which 89.1% (1489) were squamous, and 10.9% (182) had adenocarcinoma or 
adenosquamous cancers (6% had adenosquamous and 4.8% had adenocarcinoma). The 
demographics of squamous and adeno- and adenosquamous carcinomas of the cervix are 
compared in Table 1. Adeno- and adenosquamous carcinomas were more often stage IB2, 
27.5% versus 20.0%, and fewer had stage IIIB, 21.4% versus 28.6%, though these 
differences were not statistically significant (p=0.102). The mean tumor size was larger for 
squamous (6.5 cm) than adeno- and adenosquamous carcinomas (5.9 cm; t-test for 
difference in means, p<0.001). Adeno- and adenosquamous carcinomas were more often 
poorly differentiated, 46.2% versus 26.9%.
The treatment regimens by tumor histology are represented in Table 2. Cisplatin-based 
chemoradiation was utilized in 56.5% of squamous cell carcinoma patients compared to 
61.5% of adenocarcinoma and adenosquamous cervical carcinoma patients. Adjusted rates 
of morbidity for adeno- and adenosquamous - vs. squamous histology are presented in table 
3. Although most toxicities were equivalent between the 2 histologies, neurologic, auditory 
and visual toxicities were more common in squamous cell carcinoma patients, while 
pulmonary toxicities were more common among adenocarcinoma and adenosquamous 
carcinoma patients.
Multivariate Cox modeling was used to analyze prognostic factors for progression-free and 
overall survival for all patients (Table 4), controlling for treatment by stratification; and for 
patients treated without concurrent cisplatin (i.e. radiation alone, radiation with 5- 
fluorouracil, and radiation with hydroxyurea) and for patients treated with concurrent 
cisplatin (i.e. cisplatin alone; cisplatin with 5- fluorouracil; cisplatin, 5- fluorouracil and 
hydroxyurea; and cisplatin with recombinant human erythropoietin) respectively. Overall 
survival was poorer for adeno- and adenosquamous carcinomas compared to squamous 
carcinomas when analyzed together. African-American race is associated with a 
significantly poorer overall survival (p=0.010) and Asian race is associated with a 
significantly improved overall survival (p=0.013). However, African-Americans did equally 
as poorly with squamous and non-squamous histologies. However, the effect of race was 
only present for patients receiving radiation without cisplatin and was not present among 
cisplatin-treated patients. Performance status 0 versus 1 and 0 versus 2 significantly affected 
overall survival p=0.019 and 0.014, respectively. For both squamous and adeno- and 
adenosquamous carcinomas there were statistically poorer overall survival rates for patients 
with stage IIB and greater stages as compared with stage IB2. Similarly, when analyzed by 
tumor size, poorer overall survival was noted for each increment in tumor size for both 
squamous and adeno- and adenosquamous carcinomas. Based on the Cox model, each 10% 
increase in tumor size was associated with a 3% increase in risk of disease progression and a 
2% decrease in overall survival.
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When treated with radiation therapy without concurrent cisplatin, the 70 patients with 
adeno- and adenosquamous carcinomas of the cervix showed a statistically slightly poorer 
overall survival (p=0.0499) compared to the 647 patients with squamous cell carcinoma of 
the cervix. (Figure 1) However, when treated with concurrent cisplatin-based chemotherapy 
during radiation therapy the 112 patients with adeno- and adenosquamous carcinomas had a 
similar progression-free (p=0.315) and overall survival (p=0.459) compared the 842 patients 
with squamous cell carcinoma (Figure 2). Adverse effects to treatment were similar among 
squamous and non-squamous patients with the exception of pulmonary toxicity seen in 1.1% 
of squamous cell patients and 3.3% of adeno- and adenosquamous carcinoma patients (and 
neurologic, auditory and visual symptoms which are slightly more common in the squamous 
cell carcinoma patients 5.4% versus 1.6%.
DISCUSSION
This is the first GOG study to retrospectively evaluate locally advanced stage adeno- and 
adenosquamous carcinomas of the cervix treated with radiation with or without concurrent 
chemotherapy. Compared to squamous carcinomas, adenocarcinoma and adenosquamous 
carcinomas were more commonly stage IB2 27% versus 20%. This is not completely 
unexpected, since in contrast to squamous cell cervical carcinoma, adenocarcinoma and 
adenosquamous carcinomas arise within the endocervical canal. As they grow, they distend 
the cervical stroma creating a barrel shaped cervix, which does to have definitive 
parametrial invasion and precludes classification as stage IIB. There was statistically poorer 
overall survival for patients with stage IIB and greater compared with stage IB2. The 
confidence intervals of stage IIB to IVA overlapped. Since large tumor size can often be 
reached with expansile endocervical tumors, we chose to analyze the effect of clinical tumor 
size on overall survival, which was poorer with increasing tumor size. However, the adverse 
effect of increasing tumor size was equal among squamous and non-squamous histologies.
Despite smaller tumor size, which should confer a better prognosis, patients with 
adenocarcinoma and adenosquamous carcinoma had a poorer overall survival when treated 
with radiation alone. There are inherent limitations to tumor measurement clinically, 
however, a previous GOG study demonstrated clinical tumor measurement was closely 
associated with progression-free and overall survival [18]. Clinical tumor measurement may 
be more significant in adeno- and adenosquamous carcinomas which occur higher in the 
genital tract. MRI was not available in the earlier years of these studies and is an option 
although not currently mandated in our most recent cervical cancer trials of chemoradiation.
The most important finding of our study is the poorer outcome noted for locally advanced 
stage adenocarcinoma and adenosquamous cancers treated with radiation without cisplatin 
when compared to squamous cancers and nullification of this difference with the use of 
concurrent cisplatin-based chemoradiation. This provides the strongest support to date for 
the use of concurrent cisplatin-based chemoradiation for locally advanced non-squamous 
cervical cancer. Recently, Wright et al characterized the molecular profile of 40 
adenocarcinomas and 40 squamous of the cervix [19]. They found significant differences in 
KRAS mutations 17.5% vs 0% and non-significant differences in EGFR mutations 0% vs 
7.5%, PIK3CA mutations 25% vs 37.5%, for adenocarcinoma and squamous carcinoma, 
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respectively. Adjusted analysis demonstrated tumors with PIK3CA mutations were 
associated with a shorter overall survival, HR=9.1. They proposed this may account for the 
differences in outcome and targeting distinct subsets of cervical cancer patients may 
improve outcome. However, since PIK3CA mutations were more common in squamous 
cancers, they should have the poorer overall survival. The current study finds a poorer 
outcome for adenocarcinoma and adenosquamous cancers compared to squamous 
carcinomas treated with radiation alone but not when treated by cisplatin-based 
chemoradiation. Toxicity of chemoradiation was very similar between the two histologies. 
Other strategies to incorporate chemotherapy into the primary radiation treatment of cervical 
cancer include adjuvant and neoadjuvant. Phase II and III studies that have used concurrent 
and post-radiation chemotherapy have demonstrated improvement in overall survival 
[5,12,20]. In these studies, it is difficult to know the relative benefit of concurrent vs 
adjuvant chemotherapy. The impact of post-radiation adjuvant chemotherapy following 
concurrent chemotherapy for locally advanced cervical cancer is unknown but is currently 
being studied in the Outback trial in which patients are randomized to adjuvant 
chemotherapy with carboplatin and paclitaxel for 4 cycles or observation following weekly 
cisplatin during radiation.[21] The impact of concurrent and adjuvant cisplatin-based 
chemoradiation on adenocarcinoma and adenosquamous cervical carcinomas was noted in 
the study of post-radical hysterectomy by Peters et al [5]. This trial administered two doses 
of cisplatin and 5-fluorouracil chemotherapy during radiation therapy and two courses 
following radiation. An improvement was noted for patients who received the post-radiation 
chemotherapy but a subset analysis by histology was not performed.
The use of both neoadjuvant and adjuvant chemotherapy with concurrent chemoradiation in 
adenocarcinomas was recently reported by Tang et al [22]. In their trial, 880 patients with 
adenocarcinoma of the cervix were randomized to concurrent chemoradiation or concurrent 
chemoradiation preceded by one cycle of neoadjuvant and two cycles of adjuvant 
chemotherapy with cisplatin and paclitaxel. Patients who received chemoradiation with 
adjuvant chemotherapy showed a significantly longer disease-free (P<.05), cumulative 
overall survival (P<.05) and long-term local tumor control (P<.05). They also had decreased 
rates of both local and distant failure (P<.05).
In summary, this analysis demonstrates that both adenocarcinoma/adenosquamous and 
squamous cell cancer appear to respond well to chemoradiation with no differences detected 
in this large retrospective analysis of prospectively collected data. The role of other 
strategies of chemoradiation awaits ongoing and future trials.
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Research Highlights
• We retrospectively analyzed histology in locally advanced cancers of the cervix 
treated in GOG randomized trials of chemoradiation.
• Adenocarcinoma or adenosquamous (non-squamous) carcinoma had a poorer 
survival compared to squamous carcinoma.
• Non-squamous patients had poorer survivals when treated with radiation 
without concurrent cisplatin but similar survival when treated with concurrent 
cisplatin.
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Figure 1. 
Overall survival for patients with squamous and adeno- and adenosquamous carcinomas 
treated with radiation alone
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Figure 2. 
Overall survival for patients with squamous and adeno- and adenosquamous carcinomas 
treated with radiation and concurrent cisplatin chemotherapy
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Table 1
Patient Characteristics by Tumor Histology
N squamous-cell carcinoma
N = 1489
adeno- & adenosq. carcinoma
N = 182
Test Statistic
Age (years) 1671 46.5 (38.8–55.9) 46.0 (54.6–39.4) P = 0.561
Race/Ethnicity 1671 P = 0.0772
  White 59.9% (892) 64.8% (118)
  Black 24.3% (362) 15.9% (29)
  Hispanic, other 12.2% (182) 15.4% (28)
  Asian 3.6% (53) 3.8% (7)
Performance status 1671 P = 0.4592
  normal, asymptomatic 70.9% (1055) 75.3% (137)
  symptomatic, ambulatory 25.4% (378) 21.4% (39)
  symptomatic, in bed 3.8% (56) 3.3% (6)
Tumor size (cm) 1659 6.0 (5.0–8.0) 6.0 (5.0–7.0) P < 0.0011
Tumor size (cm) 1659 P = 0.0052
  < 5.0 15.8% (234) 22.5% (41)
  5.0–6.0 18.8% (278) 24.7% (45)
  6.0–7.5 38.9% (575) 35.2% (64)
  ≥ 7.5 26.4% (390) 17.6% (32)
FIGO stage 1671 P = 0.1022
  IB2 20.0% (298) 27.5% (50)
  IIB 47.1% (702) 47.3% (86)
  IIIA 1.3% (20) 1.6% (3)
  IIIB 28.6% (426) 21.4% (39)
  IVA 2.9% (43) 2.2% (4)
Tumor grade (differentiation) 1671 P < 0.0012
  well 5.5% (82) 14.3% (26)
  moderate 65.3% (972) 37.9% (69)
  poor 26.9% (400) 46.2% (84)
  not graded 2.4% (35) 1.6% (3)
Hydronephrosis 1671 P = 0.62
  none 88.9% (1324) 91.2% (166)
  unilateral 8.8% (131) 6.6% (12)
  bilateral 2.3% (34) 2.2% (4)
Parametrial involvement 1671 P = 0.1082
  none 21.7% (323) 28.6% (52)
  unilateral 46.3% (689) 42.9% (78)
  bilateral 32.0% (477) 28.6% (52)
Pelvic nodes 1671 P = 0.0332
  positive 10.3% (154) 15.9% (29)
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N squamous-cell carcinoma
N = 1489
adeno- & adenosq. carcinoma
N = 182
Test Statistic
  negative 62.8% (935) 63.2% (115)
  unknown 26.9% (400) 20.9% (38)
b (a–c) represent the lower quartile a, the median b, and the upper quartile c for continuous variables.
N is the number of non–missing values.
Numbers after percents are frequencies.
Tests used:
1Wilcoxon test;
2
Pearson test
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Table 2
Treatment Regimen by Tumor Histology
N squamous-cell
carcinoma
N = 1489
Adeno/adenosquamous
carcinoma
N = 182
Treatment 1671
  RT 11.6% (173) 14.3% (26)
  RT+5FU 8.9% (133) 12.1% (22)
  RT+HU 22.9% (341) 12.1% (22)
  RT+CDDP 32.6% (485) 37.4% (68)
  RT+CDDP+5FU 10.4% (155) 11.5% (21)
  RT+CDDP+5FU+HU 10.2% (152) 10.4% (19)
  RT+CDDP+rHuEPO 3.4% (50) 2.2% (4)
RT = Radiation therapy
5FU = 5-fluorouracil
HU = hydroxyurea
CDDP = cis-diamminedichloroplatinum
rHuEPO = recombinant human erythropoietin
N is the number of non–missing values.
Numbers after percents are frequencies.
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Table 3
Adjusted Rates of Morbidity for Adeno- vs. Squamous Histology
Variable Odds ratio* 95% CI
Toxicity
  WBC 0.85 0.60–1.18
  peripheral neuropathy 0.87 0.13–3.35
  neurologic, auditory, visual 0.32 0.08–0.89
  other hematologic 0.74 0.52–1.06
  skin 1.00 0.56–1.68
  genitourinary 0.98 0.57–1.61
  lymphatic 2.15 0.29–10.24
  gastrointestinal, hepatic 0.91 0.65–1.26
  constitutional, fever 0.82 0.43–1.44
  pulmonary 3.05 1.04–7.91
  allergy, immunological 0.99 0.05–5.78
  cardiovascular 1.52 0.56–3.54
  other 0.84 0.47–1.43
*Adjusted for age, race, performance status, tumor size, stage, grade, and treatment.
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